BEIJING and SHANGHAI and BOSTON, Jan. 8, 2023 /PRNewswire/ — Jacobio Pharma (1167.HK) announced it has completed the first patient dosage of its in-house R&D drug candidate Aurora A Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S.
JAB-2485 is a highly selective small molecule Aurora A inhibitor. At present, there is no commercialized Aurora A inhibitor globally. Jacobio’s self-developed JAB-2485 is the third Aurora A inhibitor entered into clinical stage in the United States. This clinical trial will be completed independently by the clinical team of Jacobio, marking the further improvement of Jacobio’s global R&D capability.
JAB-2485 has good anti-tumor activity. Preclinical data show that JAB-2485 is highly selective at biochemical and cellular levels. The inhibitory activity of Aurora A is one thousand times higher than that of Aurora B, and has potential to benefit patients with small cell lung cancer and triple-negative breast cancer.
Relevant studies have shown that Aurora A and SHP2 inhibitors may be one of the therapies to solve the drug resistance of KRAS G12C inhibitors, and is also expected to enhance the anti-tumor effect in combination with BET inhibitors. Jacobio has these three self-developed drugs in clinical stage, including SHP2 inhibitors (JAB-3312, JAB-3068), Aurora A inhibitor (JAB-2485), KRAS G12C inhibitors (JAB-21822), and BET inhibitors(JAB-8263), which has potential to provide more combination therapies to patients.
About clinical study of JAB-2485
The clinical study of JAB-2485 (NCT05490472) is an open, phase I/IIa international multicenter study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of JAB-2485 in the treatment of advanced solid tumors. This global multicenter study will enroll 102 patients and is expected to be completed in August 2026.
Jacobio(1167.HK) is committed to providing more products and solutions to people’s health. Our mission is to provide compelling innovations for creating a pipeline of life-changing medicines. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. The company’s R&D centers are located in Beijing, Shanghai and MA, with a platform and expertise in developing allosteric inhibitors against protein tyrosine phosphatase, KRAS and transcriptional factors.
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the Company, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment, and political, economic, legal and social conditions in China.
The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.